GTS Securities’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

GTS Securities’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.78M	Sell	26,885 -6,168	-19%	-$361K	0.04%	273
2026 Q1	$1.79M	Buy	33,053 +10,504	+47%	+$585K	0.06%	230
2025 Q4	$1.26M	Sell	22,549 -5,221	-19%	-$271K	0.04%	350
2025 Q3	$1.33M	Buy	27,770 +8,822	+47%	+$395K	0.05%	311
2025 Q2	$769K	Buy	18,948 +641	+4%	+$25.8K	0.03%	467
2025 Q1	$802K	Buy	+18,307	New	+$808K	0.03%	474
2024 Q4	–	Sell	-25,284	Closed	-$1.12M	–	4230
2024 Q3	$1.12M	Buy	25,284 +18,308	+262%	+$784K	﹤0.01%	2056
2024 Q2	$278K	Sell	6,976 -24,898	-78%	-$1.01M	﹤0.01%	3191
2024 Q1	$1.37M	Buy	31,874 +19,712	+162%	+$849K	﹤0.01%	1741
2023 Q4	$506K	Buy	+12,162	New	+$461K	﹤0.01%	2786

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Evelyn Partners London $46.9B AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

GTS Securities's XPH Position: Q2 2026 in Review

GTS Securities reduced its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 19% in Q2 2026, selling an estimated $361K and leaving 26,885 shares worth $1.78M. The position accounts for 0.04% of the portfolio, ranked #273.

GTS Securities first reported a position in XPH in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.79M in Q1 2026. 93 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

GTS Securities held 26,885 shares of State Street SPDR S&P Pharmaceuticals ETF worth $1.78M as of Q2 2026.
GTS Securities sold 6,168 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $361K.
State Street SPDR S&P Pharmaceuticals ETF made up 0.04% of GTS Securities's portfolio in Q2 2026, its #273 holding.
GTS Securities first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q4 2023 and has held it in 10 quarters since.
GTS Securities's State Street SPDR S&P Pharmaceuticals ETF position peaked at $1.79M in Q1 2026.
93 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.